Viewing profile — davemessina

Hi Jake, While we have no immediate plans to hire out west, we are changing rapidly and that certainly could change in the future. We'll be offering our test to patients through do…

I am not an expert in gene therapy, but I think getting the transcription or translation machinery to read the "good" copy instead of the stop codon would be the challenge there. c…

Hi everyone! Dave Messina from Cofactor Genomics here. I'd be happy to answer any questions you might have.

Over half of the YC companies (us included) don't really need the money. The $120k investment is only a small part of what YC does. See http://www.ycombinator.com/atyc/

Yes.

Thanks for your comments, and yes, you've got it exactly. In cancer, both DNA and RNA can be effective diagnostics, and there's been a lot of great work on the DNA side in cancer. …

That some circRNAs are lower in cancer than in normal tissue is a reliably detectable difference and is precisely what makes them an excellent biomarker. There's additional evidenc…

It's the fastest way for us to get this powerful diagnosis technology on the market and helping people. We believe that our RNA test can become a routine part of a doctor's visit, …

Hi Daniel, We've filed patents on our work. Is there any biotech patent landscape as bad as RNAi? :)

Here's a good place to start: http://dx.doi.org/10.1038/cr.2015.82

We are looking at Parkinson's, heart disease, and cancer initially.

We plan to offer testing through your doctor, rather than direct to consumer. We are measuring circular RNAs.

Hi, Great question. We're developing tests around a recently discovered type of RNA called circular RNA. Tissue-specific circular RNAs are present in blood, and so that's how it's …

Hi everyone! Dave Messina from Cofactor Genomics here. I'd be happy to answer any questions you might have. We're excited to launch!